ABSTRACT:
Introduction & Objective: Diabetes is regarded as a serious condition for both the individual and the society. One of the most important mortality reasons in diabetic patients is atherosclerosis. Many epidemiological studies have shown that the total homocysteine concentration is a risk indicator for cardiovascular disease. Malondialdehyde (MDA) also is a highly toxic by-product formed in part by lipid oxidation derived free radicals. Many studies have shown that its concentration increases considerably in diabetes mellitus. Epidemiological data indicate that the consumption of omega-3 unsaturated fatty acids (O3FA) leads to a reduction in cardiovascular disorders may protect against metabolic diseases. In recent years, numerous researches on omega-3 fatty acids have been done but it cannot be used as a confident additive. So in order to evaluate and compare the effects of ω3 on malondialdehyde (as fat peroxidation indicator) and homocysteine on diabetic type 2 patients, this research was carried out in Tehran University.
Materials & Methods: A randomized double blind placebo controlled clinical trial was conducted on 81 type 2 diabetic patients, 45–85 years old with diabetes for at least 2 years.Diabetic patients were randomly assigned to one of the case or control groups, each subject received 3 capsules per day of omega-3 or placebo for a period of 2 months. 10 ml blood was collected from each subject at the beginning and at the end of a 2-month trial. Serum MDA was determined with Tiobarbituric acid for more sensitivity and homosystein was measured by Hitachi autoanalyzer with Enzymatic Cycling method. Nutrients intakes were estimated using 24 h dietary recall questionnaire at the beginning and at the end of the 2-month trial for 2 days and analyzed by FPп. T-test also was used to compare groups.
Results: Copmaring the mean±S.D of BMI and food intake in both groups showed no significant differences. MDA level degreased 0.72 nmol/ml in case group but the difference with the control group was not significant but the differences of homosystein level in case (3.10µmol/lit) and control (0.126µmol/lit) groups were significant.
Conclusion: Consumption of omega-3 fatty acids supplementation (3 gr/per day) in capsul form can decrease the serum level of homocysteine in diabetic patients without inducing any changes in MDA level and lipid peroxidation.
Jalali M, Pouya S, Eshraghian A, Rajab A, Chamari M, Fatehi F et al . Effects of ω3 on Serum Level of Malondialdehyde and Homocysteine in Type 2 Diabetic Patients. armaghanj 2008; 12 (4) :45-53 URL: http://armaghanj.yums.ac.ir/article-1-664-en.html